Intriguingly, AZD9592 in vitro efficacy was most robust when both EGFR and c-MET were engaged, suggesting that bispecific targeting of EGFR and c-MET may increase tumor selectivity and reduce on-target toxicities [144]. The gene discussed is MET; the disease is neoplasm.